{"schema_version":"secwatch.filing_event.v1","accession":"0001193805-22-001152","form_type":"8-K","ticker":"ARCT","cik":"0001768224","company_name":"Arcturus Therapeutics Holdings Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.967121+00:00","generated_at":"2026-06-24T02:12:44.057011+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcturus Q2 revenue $27.1M, net loss $0.82/share; ARCT-154 booster shows durable Omicron response","bullets":["Revenue $27.1M (vs $2.0M Q2 2021); net loss $21.6M ($0.82/sh) improved from $54.6M ($2.07/sh) year ago.","ARCT-154 booster: 44-fold (BA.1) and 39-fold (BA.2) neutralizing antibody GMFR at Day 91.","ARCT-810 gets EU Orphan Medicinal Product Designation for OTC deficiency; Phase 2 study enrolling.","ARCT-154 EUA in Vietnam delayed to Q4 2022; registrational booster study expected Q4 2022.","Cash $283.5M at June 30, down from $370.5M at Dec 2021; expected to fund ops into late 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193805-22-001152","json":"https://secwatch.observer/filing/0001193805-22-001152.json","markdown":"https://secwatch.observer/filing/0001193805-22-001152.md","text":"https://secwatch.observer/filing/0001193805-22-001152.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001152/0001193805-22-001152-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1768224/000119380522001152/e621864_8k-arct.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:12:44.057011+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}